IND MICROMET PDF

D93 is a recombinant humanized IgG1 monoclonal antibody that inhibits angiogenesis, tumor cell growth and metastasis by targeting cleaved collagen, which is predominantly produced in the extracellular matrix of tumors. Preclinical studies indicate that D93 has the potential to treat different types of cancer as a single agent and in combination with chemotherapeutics. Because of its anti-angiogenic activity, D93 may also provide a new therapeutic approach for other diseases involving neo-vascularization such as wet age-related macular degeneration or proliferative diabetic retinopathy. Food and Drug Administration for clinical testing of D93 in patients with cancer. In addition, Micromet will receive royalties on worldwide sales of D

Author:Daigar Kagis
Country:Malawi
Language:English (Spanish)
Genre:Technology
Published (Last):19 April 2019
Pages:162
PDF File Size:15.40 Mb
ePub File Size:4.65 Mb
ISBN:122-4-38004-717-3
Downloads:81216
Price:Free* [*Free Regsitration Required]
Uploader:Sham



CEA is a protein found on the surface of a number of gastrointestinal cancers, including colorectal, esophageal and gastric. MedImmune anticipates initiating the Phase I trial in the first half of Typically, antibodies cannot engage T cells because T cells lack the appropriate receptors for binding antibodies. BiTE antibodies have been shown to bind T cells to tumor cells, ultimately inducing a self-destruction process in the tumor cells referred to as apoptosis, or programmed cell death.

In the presence of BiTE antibodies, T cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at very low concentrations. Through the killing process, T cells start to proliferate, which leads to an increased number of T cells at the site of attack.

Micromet, Inc. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including Bayer Schering Pharma, Boehringer Ingelheim, MedImmune, Merck Serono, Nycomed and sanofi-aventis. Additional information can be found at www. This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of and other federal securities laws.

Any statements contained herein that do not describe historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements.

These forward-looking statements include statements regarding the development and commercialization of MT, including the timeline for the initiation of the phase 1 clinical trial.

Micromet cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Micromet also disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Jennifer Neiman Director, Corporate Communications jennifer.

About Micromet, Inc. Safe Harbor Statement This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of and other federal securities laws. Contacts Micromet, Inc. Log In Sign Up.

ALEXANDER LANGSDORF ELECTRICAL MACHINES PDF

PRESS RELEASE

CEA is a protein found on the surface of a number of gastrointestinal cancers, including colorectal, esophageal and gastric. MedImmune anticipates initiating the Phase I trial in the first half of Typically, antibodies cannot engage T cells because T cells lack the appropriate receptors for binding antibodies. BiTE antibodies have been shown to bind T cells to tumor cells, ultimately inducing a self-destruction process in the tumor cells referred to as apoptosis, or programmed cell death. In the presence of BiTE antibodies, T cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at very low concentrations. Through the killing process, T cells start to proliferate, which leads to an increased number of T cells at the site of attack. Micromet, Inc.

IBM ESQL TUTORIAL PDF

Taking this next step toward an IND-filing triggers a 2. The product candidate, which is being developed for the treatment of patients with solid tumors, was generated by Micromet using its proprietary BiTE technology. Micromet is primarily responsible for the preclinical development of the BiTE antibody, and will collaborate with Bayer Schering Pharma through the completion of Phase 1 clinical trials. After completion of Phase 1 trials, Bayer Schering Pharma will assume full control of clinical development and commercialization of the BiTE antibody. Micromet is eligible to receive progress-dependent milestone payments and up to double-digit royalties on future potential tiered net sales of this product candidate. Typically, antibodies cannot engage T cells because T cells lack the appropriate receptors for binding antibodies.

DL380 G7 QUICKSPECS PDF

.

BF256A DATASHEET PDF

.

Related Articles